Delving into the Latest Updates on Othera Pharmaceuticals, Inc. with Synapse

Overview

The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular hypertension. It will be compared with commercial timolol and placebo eye drops.

Start Date01 Sep 2008

Sponsor / Collaborator

Othera Pharmaceuticals, Inc.

NCT00485394 / Unknown statusPhase 2

A Randomized, Double-Masked, Dose-Ranging, Multi-Center, Phase II Study Comparing the Safety and Efficacy of OT-551 With Placebo to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration

The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.

Start Date01 Jun 2007

Sponsor / Collaborator

Othera Pharmaceuticals, Inc.

NCT00306488 / CompletedPhase 2IIT

A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration

Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration. This pilot study of up to 10 eye drop tolerant participants with bilateral geographic atrophy is designed to characterize the effect of 0.45% concentration of OT-551 eye drops given 3 times a day on the progression of geographic atrophy area over a two-year period. Participants will have one eye randomized to receive the eye drop and the fellow eye will be observed only.

Start Date01 Mar 2006

Sponsor / Collaborator

National Institutes of Health Clinical Center

[+2]

100 Clinical Results associated with Othera Pharmaceuticals, Inc.

Login to view more data

0 Patents (Medical) associated with Othera Pharmaceuticals, Inc.

Login to view more data

1

Literatures (Medical) associated with Othera Pharmaceuticals, Inc.

16 Nov 2008·Blood

Modulation of Cancer Cell-Associated Procoagulant Activity (PCA) by a Novel, Small Molecule, Orally Active Inhibitor of Oxidative Stress Pathways

Author: Mousa, Shaker S ; Dier, Emmy ; Patil, Ghanshyam ; Kannanayakal, Theresa ; Lansing, Lawrence ; Mousa, Shaymaa S. ; Rickles, Frederick

AbstractBackground: The association between malignancy and venous thromboembolism (VTE) is well-recognized. VTE is associated with a systemic hypercoagulable state that is secondary to cancer, cancer-associated therapy and the host inflammatory response. We have tested the ability of OT-304, which is a dual inhibitor of reactive oxygen species (ROS)-mediated activation of both the EGR-1 and NF-κB pathways, to inhibit the PCA of tumor cells.Methods: Molecular measurements of NF-kB (p50/p65), IkBa, TNF-a, EGR1 and tissue factor (TF) were performed on the human monocytic cell line THP-1, and human umbilical vein endothelial cells (HUVECs) using Affymetrix micro-array, RTPCR, Western blot, ELISA and gel shift assays. The cell-based, anticoagulant efficacy of OT-304 at 1–30 mM was determined in in vitro models of both pro-inflammatory and cancer cell-associated hypercoagulable states, using thrombelastography (TEG) in human blood and in a rabbit model of cell-based coagulation activation.Results: OT-304 effectively inhibited LPS-mediated TNF-α production in human blood and in THP-1 cells, with an IC50 of 6.7 mM. Similarly, in mice, in a dose-dependent manner, OT-304 at 0.1–50mg/kg IP or 1.0–150 mg/kg oral, inhibited LPS-induced NF-κB activation-associated up-regulation of various chemokines and cytokines. At the molecular level, OT-304 demonstrated effective inhibition of LPS-induced NF-κB activation, nuclear translocation of p50/p65, degradation of IKBa, without any effect on nuclear p50/p65 DNA binding. OT-304 appeared to induce modest down-regulation of the key procoagulant mediator TF, presumably via the inhibition of EGR1. In human whole blood subjected to TEG, OT-304 inhibited the procoagulant effect induced by LPS, lipid hydroperoxide, and ceramide, without directly affecting factor Xa, factor IIa or other coagulation factors. Additionally, OT-304 at 0.1–10 mM inhibited the PCA of glioma, lung, and pancreatic cancer cells. In comparison to the low-molecular-weight heparin, enoxaparin, OT-304 (1–30 ug/ml) was without any significant effect on soluble blood coagulation, as measured by the activated partial thromboplastin time. Repeated administration of OT-304 to mice (10 mg/kg, IP daily for up to 14 days), was without any hemorrhagic toxicity as compared to enoxaparin administered at the same dose. In a mouse xenograft model of human glioma, OT-304 (30 mg/kg, IP, daily for 15 days) resulted in significant inhibition of tumor growth, tumor angiogenesis, and glioma-associated elevation of plasma D-dimer. In rabbits, OT-304 (10 mg/kg IP) resulted in significant inhibition of LPS-induced PCA.Conclusions: OT-304, by virtue of its ability to target and modulate more than one pathway, may represent a promising anti-cancer therapy, capable of inhibiting tumor growth, inflammation and cancer-associated thrombosis without compromising hemostasis.

100 Deals associated with Othera Pharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Othera Pharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

OT-551 ( SOD1 )	Nuclear cataract More	Discontinued
OT-300 series ( NF-κB )	Neoplasms More	Pending
QLT-091568 ( β-adrenoceptors )	Glaucoma, Open-Angle More	Pending